← Back to Clinical Trials
Recruiting NCT07586397

NCT07586397 HIPS Feasibility Randomized Controlled Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07586397
Status Recruiting
Phase
Sponsor Massachusetts General Hospital
Condition Hip Pain Chronic
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-07-20
Primary Completion 2027-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
HIPS-1HIPS-2

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-07-20 with a primary completion date of 2027-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to conduct a randomized controlled trial (RCT) to test the feasibility of two dose- and time-matched pain management programs, delivered via live video, for adults with chronic (lasting at least 3 months) and non-arthritic hip-related pain (HRP). Following pre-determined benchmarks, findings from this trial will be used to assess the feasibility, credibility, and acceptability of both programs (HIPS-1, HIPS-2). In preparation for a future clinical trial powered to test efficacy, we will optimize the protocol for patient recruitment, study protocol, and fidelity materials.

Eligibility Criteria

Inclusion Criteria: 1. Presenting with chronic (lasting ≥3 months) hip joint-related pain 2. Fluent in English 3. Age ≥18yr \[If ≥45yr, the physician will confirm no osteoarthritis via X-ray (Kellgren Lawrence \[KL\] grade 0-1)\] 4. Score ≥3 for current hip pain on the Pain-VAS 5. Psychological risk factor for the maintenance of pain by meeting ≥1 of the criteria listed below: 1. Score ≥ 20 on the PCS 2. Score ≤ 40 on the PSEQ 3. Score ≥ 17 on the TSK-11 6. Exhibits sedentariness or dissatisfaction with physical activity by meeting ≥1 of the criteria listed below: 1. Physically active \< 150mins/week according to the IPAQ-SF 2. Hip pain interferes with the ability to be physically active 3. Dissatisfaction with the current physical activity level Exclusion Criteria: 1. Previous surgery on the symptomatic (painful) hip 2. Current pain referred from the lower back

Contact & Investigator

Central Contact

Kate Jochimsen, PhD, ATC

✉ kjochimsen@mgh.harvard.edu

📞 920-948-7812

Principal Investigator

Kate Jochimsen, PhD, ATC

PRINCIPAL INVESTIGATOR

Massachusetts General Hospital

Frequently Asked Questions

Who can join the NCT07586397 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hip Pain Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07586397 currently recruiting?

Yes, NCT07586397 is actively recruiting participants. Contact the research team at kjochimsen@mgh.harvard.edu for enrollment information.

Where is the NCT07586397 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT07586397 clinical trial?

NCT07586397 is sponsored by Massachusetts General Hospital. The principal investigator is Kate Jochimsen, PhD, ATC at Massachusetts General Hospital. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology